Study guide

15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus

UEMS European Board of Dermatovenereology Diploma Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Eligibility & Examination Regulations

1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition

2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology

2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns

3 Chapter 3: Dermatopathology & Diagnostic Procedures

3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy

4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology

4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance

5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease

5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders

6 Chapter 6: Hair, Nails & Pigmentary Disorders

6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation

7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease

7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses

8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease

8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease

9 Chapter 9: Autoimmune Bullous Diseases

9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis

10 Chapter 10: Eczematous Disorders, Urticaria & Allergology

10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy

11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis

11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses

12 Chapter 12: Paediatric & Genetic Dermatology

12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa

13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections

13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections

14 Chapter 14: Viral & Fungal Cutaneous Infections

14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses

15 Chapter 15: Sexually Transmitted Infections & Genital Infections

15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis

16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine

16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems

17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours

17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases

18 Chapter 18: Melanocytic Naevi & Melanoma

18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma

19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas

19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas

20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing

20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy

21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures

21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy

22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision

22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review

15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus

Key Takeaways Explain This Topic AI

Cutaneous manifestations track CD4 T-cell decline in HIV: acute seroconversion presents with morbilliform rash and aphthoid ulcers; moderate decline (CD4 200-500) features florid seborrhoeic dermatitis, multidermatomal zoster, and non-scrapable oral hairy leukoplakia (EBV); severe decline (CD4 <200) triggers Kaposi sarcoma, bacillary angiomatosis, and crusted scabies.

Bacillary angiomatosis (Bartonella henselae/quintana) mimics Kaposi sarcoma clinically but is distinguished histopathologically by lobular vascular proliferation with neutrophils, leukocytoclasia, and positive Warthin-Starry silver staining; it responds rapidly to oral erythromycin or doxycycline.

Immune Reconstitution Inflammatory Syndrome (IRIS) represents paradoxical exacerbation of opportunistic infections following cART initiation; combination antiretroviral therapy must be maintained while administering pathogen-targeted antimicrobial and anti-inflammatory therapy.

Partner notification lookback windows are pathogen-specific: primary syphilis 3 months, secondary or early latent syphilis up to 2 years (IUSTI), gonorrhoea 3 months, and chlamydia 6 months; epidemiological treatment of recent contacts should be considered.

Anogenital Lichen Sclerosus causes porcelain-white, cigarette-paper atrophic plaques in a figure-of-eight distribution sparing the vaginal mucosa, posing a 4-5% risk of squamous cell carcinoma; first-line therapy is ultra-potent topical corticosteroids (clobetasol propionate 0.05% ointment). In contrast, erosive Lichen Planus characteristically involves the internal vaginal mucosa.

Last updated: September 2026

  • 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus
  • Cutaneous Markers and Stage-Defining Dermatoses in HIV Infection

Cutaneous manifestations occur in over 90% of individuals living with human immunodeficiency virus (HIV) across the trajectory of infection. The morphology, clinical severity, and atypicality of skin disorders correlate inversely with the peripheral blood CD4+ T-lymphocyte count, serving as vital sentinel markers of immune depletion.

1. Acute HIV Seroconversion Syndrome (Primary HIV Infection)

Develops 2 to 6 weeks after initial viral inoculation, coinciding with peak viremia and a precipitous transient drop in CD4+ T-cell count:

Systemic Syndrome: Resembles infectious mononucleosis, presenting with high fever, lethargy, pharyngitis, generalized non-tender lymphadenopathy, arthralgias, and myalgias.

Cutaneous Exanthem: Symmetrical, non-pruritic, erythematous maculopapular (morbilliform) eruption distributed predominantly over the upper trunk, neck, and face, with occasional palmoplantar involvement. Lesions resolve spontaneously within 1 to 2 weeks.

Mucosal Ulcerations: Hallmark feature consisting of painful, well-demarcated, shallow aphthoid ulcerations on the oral mucosa, pharynx, esophagus, or anogenital region.

Diagnostic Confirmation: Standard 4th-generation antibody/antigen combo assays may be indeterminate or antibody-negative during the initial "window period"; diagnosis is confirmed by plasma HIV-1 RNA viral load testing and reactive p24 antigen .

2. Early to Moderate Immune Suppression (CD4 200–500 cells/µL)

Severe Seborrhoeic Dermatitis: Highly characteristic marker. Unlike classic seborrhoeic dermatitis, in HIV it presents as extensive, refractory, intensely erythematous, inflammatory plaques with greasy yellowish scales, expanding beyond typical seborrhoeic zones to involve the malar face, eyebrows, beard, neck, chest, and intertriginous vaults. The severity mirrors rising Malassezia yeast density and worsening immunosuppression.

Oral Hairy Leukoplakia (OHL): Driven by opportunistic Epstein-Barr Virus (EBV) lytic replication in tongue squamous epithelium. Presents as asymptomatic, white, corrugated, vertically folded, non-removable plaques along the lateral borders of the tongue . Crucial exam discriminator: Oral hairy leukoplakia CANNOT be scraped off with a tongue depressor or gauze, in sharp contrast to oral pseudomembranous candidiasis (thrush), which scrapes off readily leaving an erythematous bleeding surface.

Pruritic Papular Eruption (PPE) of HIV / Eosinophilic Folliculitis: Intensely pruritic, chronic, dome-shaped, follicular and non-follicular erythematous papules distributed symmetrically across the trunk and extremities. Characterized histologically by marked perifollicular eosinophilic infiltration and clinically by intractable excoriations and post-inflammatory hyperpigmentation. Improves markedly with combination antiretroviral therapy (cART) and narrowband UVB phototherapy.

Herpes Zoster (Shingles): Severe, multidermatomal, recurrent, or necrotic varicella-zoster virus reactivation in a young adult is an absolute clinical indication for diagnostic HIV screening.

Proximal Subungual Onychomycosis (PSO): Rapid invasion of the nail bed from beneath the proximal nail fold caused by Trichophyton rubrum ; recognized clinical indicator of HIV-induced cellular immunodeficiency.

3. Severe Immune Suppression (CD4 < 200 cells/µL / AIDS-Defining)

Kaposi Sarcoma (KS): Low-grade vascular neoplasm driven by Human Herpesvirus 8 (HHV-8 / KSHV) . Most common HIV-associated malignancy. Manifests as violaceous, reddish-brown, or purplish macules and patches that progress to indurated plaques and compressible nodules, characteristically oriented along skin cleavage lines ( Langer's lines ). Prominently affects the tip of the nose, ears, trunk, lower extremities, and oral cavity (especially the hard palate and gingiva). Histopathology shows proliferation of spindle cells forming slit-like vascular channels containing extravasated erythrocytes, hemosiderin pigment, and hyaline globules; immunohistochemistry is positive for HHV-8 LANA-1 and endothelial markers (CD31, CD34, ERG, podoplanin/D2-40). First-line therapy is cART; systemic liposomal doxorubicin is indicated for visceral involvement.

Bacillary Angiomatosis (BA): Infectious vascular proliferative pseudoneoplasm caused by fastidious Gram-negative bacilli: Bartonella henselae (reservoir: domestic cat / cat flea) and Bartonella quintana (reservoir: human body louse). Clinically mimics Kaposi sarcoma or pyogenic granulomas, presenting with multiple red, violaceous, vascular, compressible, pedunculated or dome-shaped subcutaneous nodules and papules that bleed easily upon contact. May disseminate to bone, liver, and spleen (peliosis hepatis). Distinguishing Histology: Lobular vascular proliferation lined by plump, protuberant ("epithelioid") endothelial cells with a dense neutrophilic infiltrate, nuclear dust (leukocytoclasia) , and granular amphophilic clumps of bacteria highlighted by Warthin-Starry silver stain . First-line therapy: Oral Erythromycin 500 mg four times daily or Doxycycline 100 mg twice daily for 3 months (rapidly curative).

Crusted (Norwegian) Scabies: Caused by massive uncontrolled hyperinfestation with millions of Sarcoptes scabiei var. hominis mites. Presents as thick, adherent, hyperkeratotic, fissured, yellow-gray crusts and psoriasiform plaques over the hands, feet, scalp, and subungual spaces. Pruritus is characteristically minimal or absent due to defective cell-mediated immunity. Highly contagious. Treatment requires multiple oral ivermectin doses (200 µg/kg on days 1, 2, 8, 9, and 15) combined with daily topical 5% permethrin.

Disseminated Cryptococcosis & Histoplasmosis: Cutaneous lesions present as umbilicated papules mimicking molluscum contagiosum across the face and neck.

4. Immune Reconstitution Inflammatory Syndrome (IRIS)

IRIS is an exaggerated, dysregulated inflammatory reaction occurring within weeks to months after starting or optimizing combination antiretroviral therapy (cART), driven by rapid recovery of pathogen-specific CD4+ T-cell immunity:

Forms of IRIS: Paradoxical IRIS (worsening of a previously diagnosed and treated infection) and Unmasking IRIS (hyperinflammatory manifestation of a previously occult, undiagnosed opportunistic infection).

Common Triggers: Mycobacterium tuberculosis , Mycobacterium avium complex, Cryptococcus neoformans , Varicella-Zoster Virus, HSV, and HHV-8 (Kaposi sarcoma flare).

Clinical Management: Do NOT discontinue cART (cessation allows viral rebound and renewed immune destruction). Provide targeted antimicrobial therapy against the underlying opportunistic pathogen. For moderate to severe disabling inflammatory flares, initiate anti-inflammatory therapy with NSAIDs or systemic corticosteroids (prednisone 0.5–1.0 mg/kg/day with gradual taper).

Master Comparative Breakdown: Kaposi Sarcoma vs. Bacillary Angiomatosis

  • Feature Kaposi Sarcoma (KS) Bacillary Angiomatosis (BA)
  • Etiological Agent Human Herpesvirus 8 (HHV-8 / KSHV) Bartonella henselae or Bartonella quintana

Clinical Morphology Violaceous, red-brown patches, plaques, and firm nodules aligned along Langer's lines; hard palate commonly involved Red, purple, vascular, dome-shaped or pedunculated pyogenic granuloma-like papules/nodules; bleed easily

Inflammatory Cellular Infiltrate Mononuclear infiltrate (lymphocytes, plasma cells, macrophages) Dense neutrophilic infiltrate with prominent nuclear dust (leukocytoclasia)

Vascular Architecture Dermal proliferation of spindle cells forming jagged, slit-like vascular spaces with extravasated erythrocytes Lobular proliferation of well-formed capillary vessels lined by plump, protuberant epithelioid endothelial cells

Special Stains / Biomarkers HHV-8 LANA-1 positive (nuclear staining); CD31, CD34, D2-40 positive Warthin-Starry silver stain positive (reveals clumps of dark extracellular bacteria)

First-Line Medical Therapy Combination antiretroviral therapy (cART); systemic liposomal doxorubicin for visceral disease Oral Erythromycin 500 mg qid or Doxycycline 100 mg bid for 3 months (curative)

Partner Notification and STI Contact Tracing Principles

Partner notification (contact tracing) represents an essential public health intervention aimed at breaking the chain of STI transmission, preventing reinfection of the index case, preventing irreversible reproductive sequelae (PID, infertility, ectopic pregnancy), and curbing vertical congenital transmission.

1. Notification Strategies

Patient Referral: The index patient assumes responsibility for informing sexual partners and encouraging them to attend clinical services. (Supported by clinic-provided notification slips or secure anonymous electronic messaging tools).

Provider Referral: The healthcare provider or dedicated venereology contact tracer confidentially contacts named sexual partners directly, without ever disclosing the index patient's identity.

Contract / Conditional Referral: A hybrid agreement where the index patient is given a designated timeframe (e.g., 48–72 hours) to notify partners, after which the healthcare provider steps in to notify untraced partners.

2. European Contact Tracing Lookback Windows

The windows below follow the 2020 IUSTI syphilis and gonorrhoea guidelines and European/UK partner-notification practice. National services may use slightly different periods.

STI Diagnosis Lookback Window for Sexual Contacts Clinical Management of Traced Contacts

Primary Syphilis 3 months (incubation period up to 90 days) Full STI screen at first visit, 6 weeks, and 3–6 months; consider immediate epidemiological treatment with benzathine penicillin G 2.4 MU IM (especially pregnant partners or those unlikely to return)

Secondary Syphilis Commonly 6 months plus symptom duration; extended up to 2 years if there has been clinical relapse (IUSTI) As above

Early Latent Syphilis Up to 2 years (IUSTI) As above

Late Latent / Unknown Syphilis Long-term sexual partners, spouses, and children (to exclude vertical congenital transmission) Full serological screening; treat if seropositive according to clinical stage

Neisseria gonorrhoeae 3 months before symptom onset or diagnosis (IUSTI); UK practice uses 2 weeks for men with symptomatic urethritis Test for gonorrhoea and other STIs; treat if positive, or treat epidemiologically if the contact may not return

Chlamydia trachomatis 6 months before diagnosis (or the last partner if longer ago); UK practice uses 4 weeks for men with symptomatic urethritis Test for chlamydia and other STIs; epidemiological treatment with doxycycline 100 mg twice daily for 7 days is commonly offered

The 60- or 90-day windows found in some sources are US (CDC) conventions.

3. Epidemiological (Presumptive) Treatment

Epidemiological treatment means treating a contact on the day of assessment, before test results are available. IUSTI advises that it should be considered for contacts of early syphilis (especially pregnant partners) unless they can attend reliably for repeat serology, and for gonorrhoea contacts who may not return. It covers the window period, when tests can still be negative, and interrupts onward transmission.

Loading diagram... Differential Algorithm for Chronic Inflammatory Anogenital Dermatoses

Anogenital Lichen Sclerosus and Lichen Planus

Inflammatory anogenital dermatoses represent a high-stakes domain in European dermatovenereology, carrying significant risks of scarring, architectural destruction, sexual dysfunction, and malignant transformation.

1. Anogenital Lichen Sclerosus (LS)

Anogenital Lichen Sclerosus is a chronic, progressive, lymphocyte-mediated inflammatory dermatosis with a strong autoimmune underpinning (frequent association with autoimmune thyroiditis, vitiligo, and circulating autoantibodies to extracellular matrix protein 1 [ECM1] ):

Epidemiology: Predominantly affects females (female-to-male ratio ~6:1). Displays a bimodal peak in prepubertal girls and postmenopausal women. In males, it affects uncircumcised boys and adult men ( Balanitis Xerotica Obliterans - BXO ).

Female Clinical Morphology: Characterized by glistening, ivory-white or porcelain-white atrophic papules coalescing into sclerotic plaques with a "cigarette-paper" or parchment-like crinkled surface . Lesions classically distribute in a symmetrical "figure-of-eight" or hourglass pattern encircling both the vulva and the perianal region. Accompanying features include follicular plugging ("delling"), purpura/ecchymoses (due to fragile dermal capillary ectasia), and painful fissuring in the interlabial and posterior fourchette folds.

Architectural Destruction: Progressive disease causes resorption and effacement of the labia minora, encasement and burial of the clitoris (clitoral phimosis), and introital stenosis causing intractable dyspareunia.

Absolute Diagnostic Discriminator: Lichen sclerosus strictly spares the non-keratinized internal vaginal mucosa! Any inflammatory involvement of the vaginal canal definitively rules out lichen sclerosus and indicates Lichen Planus, pemphigoid, or infection.

Male Clinical Morphology (BXO): Involves the glans penis, prepuce, and urethral meatus as sclerotic, porcelain-white plaques. Complications include secondary non-retractile phimosis, recurrent balanitis, meatal stenosis with obstructive voiding, and painful erections.

Histopathology:

Hyperkeratosis with prominent follicular plugging.

Atrophy of the stratum spinosum with hydropic/vacuolar degeneration of the basal cell layer.

Broad, pale, edematous zone of homogenized collagen sclerosis / hyalinization in the upper papillary dermis, entirely devoid of elastic fibers.

Band-like (lichenoid) lymphocytic infiltrate pushed deep beneath the sclerotic zone.

Malignancy Risk: Untreated or chronically active lichen sclerosus confers a 4% to 5% lifetime risk of developing invasive squamous cell carcinoma (cSCC) of the vulva or penis. Malignancy develops through an HPV-negative pathway driven by TP53 mutations arising from differentiated vulvar intraepithelial neoplasia (dVIN) . Regular long-term specialist surveillance is mandatory.

European First-Line Treatment:

Topical Corticosteroid Regimen: Ultra-potent topical corticosteroid (Clobetasol propionate 0.05% ointment) applied on a tapering schedule: once daily at night for 1 month, alternate nights for 1 month, twice weekly for 1 month, followed by long-term intermittent maintenance. Ointment base is mandatory (creams sting and contain sensitizing preservatives).

Second-Line: Topical calcineurin inhibitors (tacrolimus 0.1% ointment).

Male BXO: Early therapeutic circumcision is curative in up to 90% to 95% of cases confined to the foreskin.

2. Anogenital Lichen Planus (LP)

Lichen planus is a T-cell-mediated autoimmune disorder targeting basal keratinocytes:

Erosive Vulvovaginal Lichen Planus: The most severe and destructive anogenital variant. Manifests as painful, fiery-red, denuded erythematous erosions of the vulva bordered by fine, delicate, reticulated, lacy white striae ( Wickham striae ).

Vaginal Involvement: Unlike lichen sclerosus, erosive lichen planus characteristically involves the internal non-keratinized vaginal mucosa , causing desquamative vaginitis with copious seropurulent yellow discharge, deep vaginal denudation, and progressive fibrotic synechiae formation leading to complete obliteration of the vaginal canal.

Vulvovaginal-Gingival Syndrome: Classic severe clinical triad characterized by erosive vulvovaginal lesions accompanied by painful desquamative gingivitis and oral mucosal Wickham striae on the buccal mucosa and tongue.

Histopathology: Hyperkeratosis, wedge-shaped hypergranulosis, irregular "saw-tooth" acanthosis, liquefaction degeneration of the basal layer, apoptotic basal keratinocytes ( Civatte / colloid bodies ), and a dense, band-like, lymphocytic infiltrate hugging the dermo-epidermal junction.

Management: Ultra-potent topical corticosteroids (clobetasol ointment for vulva; hydrocortisone acetate suppositories or budesonide foam for intravaginal erosions); systemic corticosteroids or immunosuppressive agents (methotrexate, mycophenolate mofetil) for severe, scarring, or recalcitrant disease.

Master Differential Table of Inflammatory and Premalignant Vulvar Dermatoses

Disease Entity Key Clinical Morphology Vaginal Canal Involvement Extragenital Features Key Histopathological Features Malignancy Risk First-Line European Therapy

Anogenital Lichen Sclerosus Porcelain-white sclerotic plaques; cigarette-paper atrophy; figure-of-eight distribution; resorption of labia Strictly spared (never involves non-keratinized vagina) Extragenital white atrophic macules on neck/trunk in 10–15% Epidermal atrophy; basal vacuolation; broad zone of upper dermal collagen hyalinization 4–5% lifetime risk of cSCC (via HPV-independent dVIN pathway) Ultra-potent topical corticosteroid (Clobetasol propionate 0.05% ointment)

Erosive Lichen Planus Fiery-red denuded erosions with delicate peripheral lacy Wickham striae ; labial agglutination Frequently involved (desquamative vaginitis, synechiae, canal stenosis) Oral desquamative gingivitis ; classic cutaneous polygonal violaceous papules Saw-tooth acanthosis; band-like lymphocytic infiltrate hugging DEJ; Civatte bodies Low risk (~1–2%) of mucosal cSCC Ultra-potent topical steroids (vulva) + intravaginal corticosteroid foam/suppositories

Lichen Simplex Chronicus Leathery, hyperkeratotic, lichenified plaques with exaggerated skin markings; severe intractable pruritus Strictly spared Concomitant atopic dermatitis, flexural eczema, or neurodermatitis Marked hyperkeratosis; massive regular acanthosis ; elongation of rete ridges; dermal fibrosis No intrinsic malignant potential High-potency topical steroids; sedating antihistamines; eliminate itch-scratch cycle

Differentiated VIN (dVIN) Unifocal white, pink, or red roughened plaque or nodule; usually superimposed on background of chronic LS Strictly spared None Atypical enlarged basal keratinocytes with abundant eosinophilic cytoplasm; TP53 mutated High and rapid progression to invasive cSCC Complete surgical excision with clear pathological margins

Usual VIN (uVIN / HSIL) Multifocal, pigmented, warty, or verrucous papules/plaques; younger women Can involve vagina (VaIN) and cervix (CIN) Perianal and anal intraepithelial neoplasia (AIN) Full-thickness nuclear atypia, loss of maturation, high mitotic figures; p16 strongly positive (HPV-driven) Moderate progression to invasive cSCC if untreated Surgical excision, CO2 laser ablation, or topical Imiquimod 5% cream